Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M [Yahoo! Finance]
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)